Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CCR4 | P51679 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31365128 | 1.00 | LMNA (0.38) | LMNAHTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL22119996 | 0.82 | LMNA (0.39) | LMNAHTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL22139945 | 0.82 | CYP1A2 (0.47) | LMNACCR4L3MBTL1ALDH1A1MEN1 | |
| SCHEMBL20840567 | 0.81 | KDM4E (0.34) | TDP1ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL22120146 | 0.80 | GAA (0.37) | CCR4GAACA2CA4PKM | |
| SCHEMBL8706883 | 0.79 | GAA (0.51) | LMNAHTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL8707599 | 0.78 | TSHR (0.39) | LMNAHTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL10257661 | 0.77 | GAA (0.36) | LMNAHTR1AADRA2AADRA2BADRA2C | |
| SCHEMBL22120070 | 0.73 | CYP1A2 (0.38) | CCR4GAAMEN1KMT2AKDM4E | |
| SCHEMBL29844244 | 0.73 | PDK2 (0.32) | LMNAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258329-B2 | Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells | MERCK SHARP & DOHME LLC (US) | 2025-03-25 | — | — | US | disclosed |
| EP-3972965-B1 | PYRIDINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3898595-B1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME LLC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20220242847-A1 | PYRIDINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME CORP. (US) | 2022-08-04 | — | — | US | disclosed |
| EP-3972965-A1 | PYRIDINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | Merck Sharp & Dohme Corp. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20220064147-A1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME CORP. (US) | 2022-03-03 | — | — | US | disclosed |
| CN-113423695-A | Pyrimidinone derivatives as selective cytotoxic agents against HIV infected cells | 默沙东公司 | 2021-09-21 | — | — | CN | disclosed |
| WO-2020236692-A1 | PYRIDINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME CORP. (US) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020131597-A1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | MERCK SHARP & DOHME CORP. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064147-A1 | PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | TYMP, PNP, CD4 | LMNA 3164/4885HTR1A 4032/4885ADRA2A 4681/4885 |
| US-20220242847-A1 | PYRIDINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS | PRUNE1, G6PD, ACIN1 | LMNA 1231/4885HTR1A 2175/4885ADRA2A 4200/4885 |
| US-12258329-B2 | Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells | TYMP, PNP, CD4 | LMNA 3164/4885HTR1A 4032/4885ADRA2A 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.